Lonza Expands Manufacturing for Cell and Gene Therapies in Geleen

Lonza has announced a strategic expansion of its capabilities to support the biopharmaceutical industry, focusing on cell and gene therapies. This growth comes with the addition of a new manufacturing facility in Geleen, Netherlands, which is set to enhance the company’s ability to produce complex biologics at scale. The facility will utilize advanced technologies to streamline production processes, catering to the increasing demand for innovative therapies in the healthcare sector.

The Geleen site will specifically focus on developing and manufacturing plasmid DNA, a key component in the production of viral vectors used in gene therapies. This expansion reflects Lonza's commitment to meeting the needs of its partners and clients, as well as supporting the broader evolution of cell and gene therapy treatments. With the new facility, Lonza aims to provide enhanced flexibility and capacity to meet the rising global demand for these specialized therapies.

Lonza’s Chief Executive Officer expressed enthusiasm about this milestone, emphasizing the company's dedication to advancing healthcare through innovation. By investing in state-of-the-art manufacturing capabilities, Lonza is positioning itself as a leader in the biopharmaceutical space, helping to accelerate the delivery of groundbreaking treatments that can transform patient care. This expansion not only enhances Lonza's production capacity but also reinforces its role as a vital partner in the development of future medical advancements.